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Abstract
Objective: We conducted a prospective, randomized, open-label, multicenter study to compare busulfan plus
fludarabine (BuFlu) with busulfan plus cyclophosphamide (BuCy) as the conditioning regimen in allogeneic
hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML) in first complete remission (CR1).
Methods: Totally 108 AML-CR1 patients undergoing allo-HSCT were randomized into BuCy (busulfan 1.6 mg/kg, q12
hours, -7 ~ -4d; cyclophosphamide 60 mg/kg.d, -3 ~ -2d) or BuFlu (busulfan 1.6 mg/kg, q12 hours, -5 ~ -2d; fludarabine
30 mg/m2.d, -6 ~ -2d) group. Hematopoietic engraftment, regimen-related toxicity (RRT), graft-versus-host disease (GVHD),
transplant related mortality (TRM), and overall survival were compared between the two groups.
Results: All patients achieved hematopoietic reconstitution except for two patients who died of RRT during conditioning.
All patients obtained complete donor chimerism by day +30 post-transplantation. The incidence of total and III-IV RRT
were 94.4% and 81.5% (P = 0.038), and 16.7% and 0.0% (P = 0.002), respectively, in BuCy and BuFlu group. With a median
follow up of 609 (range, 3–2130) days after transplantation, the 5-year cumulative incidence of TRM were 18.8 ± 6.9% and
9.9 ± 6.3% (P = 0.104); the 5-year cumulative incidence of leukemia relapse were 16.5 ± 5.8% and 16.2 ± 5.3% (P = 0.943);
the 5-year disease-free survival and overall survival were 67.4 ± 7.6% and 75.3 ± 7.2% (P = 0.315), and 72.3 ± 7.5%
and 81.9 ± 7.0% (P = 0.177), respectively in BuCy and BuFlu group.
Conclusion: Compared with BuCy, BuFlu as a myeloablative condition regimen was associated with lower
toxicities and comparable anti-leukemic activity in AML-CR1 patients undergoing allo-HSCT.
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Background
Acute myeloid leukemia (AML) is one of the most
common leukemias with a 20% 5-year event-free survival
in adults. The incidence of AML increases sharply with
age [1]. Allogeneic hematopoietic stem-cell transplant-
ation (allo-HSCT) is an effective and potentially curative
treatment for AML [2,3]. The conditioning regimen with
busulfan plus cyclophosphamide (BuCy) is considered as
the standard myeloablative regimen for AML. However,
it is associated with significant risks of regimen-related
toxicity (RRT) as well as transplant related mortality
(TRM), especially for the elderly and those with comorbid-
ities. Although the introduction of intravenous busulfan has
been associated with a decreased incidence of RRT, the
incidence of fatal hepatic veno-occlusive disease (HVOD)
remains high. Interactions between busulfan and cyclo-
phosphamide might result in increased liver toxicity [4].
Recently, to decrease the incidence of RRT and TRM, flu-
darabine, a strongly immunosuppressive purine analog with
considerable anti-neoplastic and immunosuppressive activ-
ity, was selected to replace cyclophosphamide in myeloabla-
tive and non-myeloablative conditioning regimens [5-12].
Non-randomized comparisons showed that myeloablative
regimen based on busulfan and fludarabine (BuFlu) might
be associated with limited extra-hematologic toxicities,
sufficient anti-leukemic effects, better overall survival (OS)
and disease free survival (DFS) for patients undergoing
HSCT compared with BuCy [8-10]. However, some studies
have documented that BuFlu was associated with an
increased risk of relapse compared with BuCy regimen,
especially in patients with active disease at the time of
transplantation [13-15]. Moreover, a recent randomized
comparison trial suggested that BuFlu regimen had sig-
nificantly lower OS and DFS than BuCy regimen for allo-
HSCT in patients with leukemia and myelodysplastic
syndrome (MDS). This randomized comparison trial
enrolled a heterogeneous group of patients including
patients with myeloid and lymphoid neoplasms, cases in
complete remission (CR) or non-remission (NR) before
transplantation [14]. There have been no randomized
studies comparing the toxicity and effectiveness of BuCy
and BuFlu as myeloablative conditioning regimens in
patients with a single disease and having a similar, balanced,
disease status at the time of transplantation.
In this study, we performed a prospective, randomized,
open-labeled, multicenter trial to compare the safety and
efficacy of BuCy and BuFlu myeloablative conditioning




This prospective, randomized, open-label, multicenter
study was conducted from January 2007 to May 2012 in
Nanfang Hospital, Southern Medical University; Zhujiang
Hospital, Southern Medical University; Guangzhou General
Hospital of Guangzhou Military Command, and Sun
Yat-Sen Memorial Hospital, Sun Yat-Sen University. The
study was performed in accordance with the modified
Helsinki Declaration. The protocol was approved by
respective ethical review boards.
Patients
Eligibility criteria included patients with AML-CR1 and
age between 12 and 60 years. Exclusion criteria included
the following: ① acute promyelocytic leukemia; ②
patients with secondary leukemia; ③ more than 3 cycles
of induction chemotherapy; ④ systolic ejection fraction
less than 30%; ⑤ abnormal pulmonary spirometry test
(percentage of the predicted value of forced expiratory
volume in first second less than 60% and/or percentage of
the predicted value of pulmonary diffusion capacity less
than 60%); ⑥ serum bilirubin or alanine aminotransferase
and/or aspartate aminotransferase two times more than
the upper limit of normal; ⑦ creatinine clearance less
than 50 ml/min. Written informed consent was obtained
from each recipient and donor.
Conditioning regimen
Eligible patients were randomized to receive BuCy or
BuFlu conditioning regimen using a permuted block
randomization. In the BuCy group, busulfan was
administered continuously for 4 hours through a central
venous catheter at 1.6 mg/kg every 12 hours on days −7
to −4, and cyclophosphamide 60 mg/kg.d was given daily
on days −3 to −2. In the BuFlu group, busulfan was given
at the same dose and schedule, and fludarabine 30mg/m2.
d was given continuously for 1 hour once daily after the
first dose of busulfan on days −6 to −2.
HLA typing and source of donor
Genomic high-resolution molecular typing was used for
HLA-A, -B, -C, -DRB1 and -DRQ. Ninety-four cases
were HLA-matched and 14 were HLA-mismatched.
Ninety three patients were transplanted from related
donors (siblings in 89 cases and family members in 4 cases),
and 15 patients from unrelated donor. Ninety eight patients
received peripheral blood stem cells (PBSCs) grafts, and 10
received bone marrow cells and PBSCs mixed grafts.
Graft-versus-host disease (GVHD) and infections
prophylaxis
Cyclosporine A (CsA, 1-3 mg/kg.d, with serum valley
value maintained at 200-300 ng/ml) plus methotrexate
(MTX, 15 mg on days +1 and 10 mg on days +3 and +6)
were administered in the patients undergoing HLA
matched sibling donor transplants for GVHD prophylaxis.
CsA, MTX and mycophenolate mofetil (MMF, 0.5 g twice a
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day on days 0 to +28) were used in the patients undergoing
1 locus HLA-mismatched sibling donor transplantation,
and CsA, MTX and human anti-thymocyte globulin (ATG
[Thymoglobulin; Genzyme, Cambridge, MA]; 2.5 mg/kg.d
on days −3 to −1) in the patients undergoing HLA-
matched unrelated donor, or more than 1 locus HLA-
mismatched sibling donor transplantation. The patients
undergoing HLA-mismatched unrelated donor or haploi-
dentical transplantation received CsA +MTX and ATG+
MMF as GVHD prophylaxis [16].
Oral sulfamethoxazole and norfloxacin were given to all
patients. Acyclovir was given daily from the beginning of
preparation therapy to engraftment, and for 7 days every 2
weeks up to 1 year after transplantation. Ganciclovir was
used for 2 weeks before transplantation for prophylaxis of
cytomegalovirus (CMV) infection, and used again during
CMV viremia periods within 1 year post-transplantation.
Antifungal agents were administered 5 days pre-
transplantation for +30 to +60 days in patients with no
history of invasive fungal infection (IFI), and at least 90 days
post-transplantation in those with a history of IFI [16].
Monitoring of epstein barr virus (EBV) -DNA and CMV-
DNA levels in blood
Generally, the EBV-DNA and CMV-DNA levels in blood
were monitored weekly for three months after transplant-
ation. During the 4th to 9th month post-transplantation,
the monitoring frequency was once every two weeks; the
10th to the 24th month, once a month; the 25th to 36th
month, once every three months. If EBV-DNA or CMV-
DNA was positive, it was monitored twice a week. The
DNA levels of EBV and CMV in blood were detected by
quantitative real-time polymerase chain reaction (RQ-PCR)
according to our method previously described [17].
Supportive care
Low molecular weight heparin (Fraxiparine, 0.6 mg i.v. con-
tinuously for 24 h) and prostaglandin E (Alprostadil, 10 mg,
3 times per day) were used from the beginning of the condi-
tioning to engraftment for HVOD prophylaxis. Phenytoin
(400 mg, 3 times per day) orally was used from 1 day before
intravenous busulfan therapy to 48 h after the discontinu-
ation of busulfan for the prophylaxis of busulfan toxicities
on central nervous system. All patients received granulocyte
colony-stimulating factor (G-CSF, 5 μg/kg.d) from +3 days
post-transplantation until achievement of the peripheral
white blood cells count reached 1.0 × 109/L or absolute neu-
trophil count (ANC) reached 0.5 × 106/L. Patients received
red blood cells and platelet transfusions if hemoglobin levels
were ≤70 g/L and platelet count ≤20.0 × 109/L.
Analysis of chimerism
Bone marrow donor-recipient chimerism on days +15 and
+30 after transplantation was evaluated using fluorescein
in situ hybridization (FISH) in sex-mismatched transplant-
ation and short tandem repeat analysis in sex-matched
transplantation.
Endpoints and definitions
The primary endpoint was RRT, and secondary endpoints
were hematopoietic engraftment, bone marrow toxicities,
the incidence and severity of acute and chronic GVHD,
early infections, disease relapse, TRM, OS and DFS after
transplantation. RRT was graded according to Bearman’s
criteria [18]. Hematopoietic engraftment was defined as the
first of 2 consecutive days with an ANC in the peripheral
blood exceeding 0.5 × 109/L and the first of 3 days with an
absolute platelet count exceeding 20 × 109/L without
transfusion support. Complete chimerism was defined as
>95% donor cells detected; mixed chimerism, as 5% to 95%
donor cells detected [16]. Acute GVHD (aGVHD) was
graded according to standard criteria, and chronic GVHD
(cGVHD) was assessed in patients alive after day 100 and
defined as limited or extensive [19,20]. Hematologic relapse
was defined by reappearance of blasts in the blood, any
manifestation of leukemia outside the hematopoietic
system, or greater than 5% blasts in the bone marrow
smear. Genetic relapse was assessed by chimerism status
and presence of the tumor target gene marker, and relapse
was defined as the rate of donor chimerism status decreas-
ing more than 5% or the reappearance of the tumor target
gene marker. TRM was defined as death from any cause
other than relapse. DFS was defined as survival in a state of
continuous complete remission.
Statistics
All patients were studied in their assigned treatment
group on an intent-to-treat analysis. Analysis was per-
formed on October 31, 2012. Comparisons of categorical
variables were made by means of chi-squared and Fisher
exact tests for small numbers. Differences between
numerical variables were calculated by means of 2-
sample t test. Incidence of time-dependent variables was
estimated by the method of Kaplan-Meier. The Cox’
regression model was used for analyzing prognostic
factors for relapse, DFS, and OS. Numerical variables
were analyzed as categories based on their values being
below or above the median of the entire cohort. Patient’s
age, gender, pre-transplantation chemotherapy cycles,
genetic subgroups, HLA-typing, donor age, the source of
grafts, conditioning regimen, mononuclear cell dose,
CD34+ cell dose, aGVHD, and cGVHD were analyzed in
univariate and multivariate analysis. Intervals were
measured from the day of transplantation until the last
day of follow-up, transplant-related death or relapse.
The SPSS software package (SPSS, Chicago, IL) was used
for all data analysis. All statistical tests were two-sided,
and P-value less than 0.05 was used to indicate statistical
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significance. The study was originally designed for 110
patients in order to detect a 10% decrease in RRT with
an α error of 0.05 and a β error of 0.10.
Results
Patient and transplant characteristics
At the time when the study was closed, a total of 110
patients were enrolled and two patients were eliminated
before randomization because of disease relapse before
transplantation. A hundred and eight patients were rando-
mized to BuCy group (n = 54) or BuFlu group (n = 54).
The median age was 30.5 years (range 12–54 years), with
56 males and 52 females. Genetic data was available in 90
patients. The genetic subgroups according to the criteria
[21] were favorable in 11 cases, intermediate in 49 cases,
and unfavorable in 30 cases . Within the study population,
4 patients had comorbidities: 1 had hypertension, 1 had
diabetes mellitus, 1 had diabetes mellitus and hyperten-
sion, and 1 had Gilbert’s syndrome and chronic bronchitis.
Two patients had a history of pulmonary tuberculosis and
28 had a history of IFI (including stable in 21 cases, and
active in 7 cases) at the time of transplantation. Character-
istics of patients, donors and transplants are summarized
in Table 1. There were no significant differences in
patients’ age, gender, induction and consolidation
chemotherapy cycles, genetic subgroups, HLA-typing,
and the source of donors and grafts between the two
groups (Table 1, all P > 0.05).
Engraftment and chimerism
All patients achieved hematopoietic reconstitution
except two patients who died of RRT during conditioning.
The median time to neutrophil engraftment were 12
(range, 9–19 days) and 11 days (range, 9–15 days), respect-
ively, in BuCy and BuFlu group (P = 0.056). The median
time to platelet engraftment were 13 (range, 9–35 days)
and 12 days (range, 9–45 days), respectively, in BuCy and
BuFlu group (P = 0.562). All 106 evaluable patients achieved
donor chimerism, including 24 cases with complete
chimerism and 30 cases with mixed donor chimerism
(with donor chimerism ranging from 78% to 93%) in
BuCy group, and 23 cases with complete chimerism
and 31 cases with mixed donor chimerism (with donor
chimerism ranging from 68% to 92%) in BuFlu group
(P = 0.845) by day 15 after transplantation. All patients
achieved complete donor chimerism by day 30 after
transplantation.
Bone marrow toxicities
The median duration of neutrophil count below 0.1 × 109/L
were 4 (range, 1–14 days) and 3 days (range, 0–9 days),
respectively, in BuCy and BuFlu group (P = 0.008). The
median duration of platelet count below 20 × 109/L were
5 (range, 1–21 days) and 3 days (range, 0–43 days),
respectively, in BuCy and BuFlu group (P = 0.043).
The median number of the red blood cell transfusion
were 2 (range, 0–7u) and 1u (range, 0–8u), respectively, in
BuCy and BuFlu group (P = 0.007). The median number of
the platelet concentrates transfusion were 3 (range, 0–19u)
and 2u (range, 0–11u), respectively, in BuCy and BuFlu
group (P = 0.028).
RRT
The most common toxicity was mucositis (60/108). The in-
cidence of total RRT were 94.4% and 81.5% (P = 0.038), and
III-IV RRT were 16.7% and 0.0% (P = 0.002), respectively, in
BuCy and BuFlu group. There were four regimen-related
deaths in BuCy group, including 1 who died from delayed
hemorrhagic cystitis, 1 who died from HVOD and 2
who died from acute heart failure; no patient died from
RRT in BuFlu group (P = 0.042). In addition, autopsy of
one patient that died from cardiac toxicity showed limited
Table 1 The characteristics of the patients
BuCy BuFlu P value
No. of patients 54 54
Sex male/female 27/27 25/29 0.700
Median age in years (range) 30.5(12 ~ 52) 30.5(14 ~ 54) 0.518
Genetic subgroups favorable/intermediate/poor risk/unknown 2/24/16/12 9/25/14/6 0.085
Induction chemotherapy cycles (range) 1 (1–3) 1 (1–3) 0.056
Consolidation chemotherapy cycles (range) 2.5 (1–4) 2 (1–4) 0.222
Source of donors related/unrelated 47/7 45/9 0.588
HLA typing matched/mismached 48/6 46/8 0.567
Source of stem cells PB /BM + PB 48/6 50/4 0.507
Cell yield (median) MNC(108/Kg) 7.87 7.22 0.510
CD34 + (106/Kg) 7.30 5.92 0.112
Abbreviations: BuCy, busulfan-cyclophosphamide; BuFlu, busulfan-fludarabine;
BM, bone marrow; PB, peripheral blood; MNC, mononucleated cell.
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myocardial fibrosis. Organ toxicities are summarized
in Table 2.
Infections post-transplantation
Within the first 100 days after transplantation, 67 patients
developed 90 episodes of bacterial and/or fungal infections.
There were 14 and 12 cases of bacterial infections, 8 and 7
cases of fungal infections, and 14 and 12 cases of bacterial
and fungal mixed infections, respectively, in BuCy and
BuFlu group (P = 0.805). One patient died from bacterial in-
fection in BuFlu group, while no patient died from bacterial
or fungal infections in BuCy group (P = 1.000). In addition,
within the 6 months of transplantation, 11 patients in BuCy
group and 10 patients in BuFlu group had CMV viremia
(P = 0.808); 4 patients in BuCy group and 4 patients in
BuFlu group had EBV viremia (P = 1.000). With a median
follow up of 609 days after transplantation, CMV asso-
ciated diseases occurred in 2 patients in BuCy group and 1
patient in BuFlu group (CMV pneumonia, P = 1.000); EBV
associated diseases occurred in 4 patients in BuCy group
[post-transplant lymphoproliferative disease (PTLD) in
3, and EBV associated fever in 1] and 3 patients in
BuFlu group (PTLD in 1, EBV associated fever in 1,
and encephalitis in 1) (P = 1.000). One patient died
from CMV pneumonia in BuCy group and 2 patients
died from EBV and CMV associated diseases in BuFlu
group (EBV encephalitis in 1 and CMV pneumonia in 1).
GVHD
The incidence of I-II° and III-IV° aGVHD were 53.8%
and 7.7%, and 44.4% and 0.0%, respectively, in BuCy and
BuFlu group (P = 0.333 and P = 0.054, respectively).
cGVHD occurred in 24 of 51 (47.1%) and 24 of 54
(44.4%) patients, respectively, in BuCy and BuFlu group
(P = 0.788). And the incidence of extensive cGVHD were
19.6% and 14.8%, respectively, in BuCy and BuFlu group
(P = 0.515). Two patients died from cGVHD in BuCy
group, while no patients died from GVHD in BuFlu group.
Relapse
During our study, 15 patients relapsed (13.0%): hematologic
relapse was detected in 6 and 6 patients, and genetic relapse
occurred in 1 and 2 patients, respectively, in BuCy and
BuFlu group (P = 0.781). The 5-year cumulative incidence
of relapse were 16.5 ± 5.8% and 16.2 ± 5.3% in BuCy and
BuFlu group (Figure 1A, P = 0.943). Of the 15 relapse
patients, 3 patients abandoned treatment and the other 12
patients were treated with chemotherapy, donor lympho-
cyte infusion or second allo-HSCT. Seven cases achieved
CR after treatment. In the univariate analysis, genetic
subgroups and HLA-typing were significantly associated
with disease relapse (P = 0.002 and P = 0.011, respectively).
In the multivariate analysis, higher genetic risk (relative risk
[RR] 2.218, CI 1.146–4.293, P = 0.018) was significantly
associated with a higher relapse rate (Table 3).
OS and DFS
With a median follow up time of 609 days (range, 3–2130)
after transplantation, 89 patients were alive and 19 patients
died. TRM occurred in 8 patients (RRT in 4, cGVHD in 2,
thrombotic microangiopathy in 1, and CMV pneumonia
in 1) in BuCy group, and 3 patients (bacterial infection
in 1, EBV encephalitis in 1 and CMV pneumonia in 1) in
BuFlu group (P = 0.112). The 5-year cumulative incidence
of TRM were 18.8 ± 6.9% and 9.9 ± 6.3% in BuCy and
BuFlu group (Figure 1B, P = 0.104). The 5-year cumulative
OS were 72.3 ± 7.5% and 81.9 ± 7.0%, respectively, in BuCy
and BuFlu group (Figure 1C, P = 0.177), and DFS were
67.4 ± 7.6% and 75.3 ± 7.2%, respectively, in BuCy and
BuFlu group (Figure 1D, P = 0.315). In the univariate
analysis, aGVHD was significantly associated with OS
(P = 0.014) and TRM (P = 0.001), and age was signifi-
cantly associated with TRM (P = 0.026). In the multivariate
analysis, severe aGVHD was significantly associated with a
lower OS (RR 5.214, CI 1.333–20.404, P = 0.018), and a
higher TRM (RR 18.538, CI 2.280–150.723, P = 0.006). All
factors studied were not significantly associated with DFS
in the univariate and multivariate analysis (Table 3).
Discussion
BuCy is considered as a standard conditioning regimen
for allo-HSCT in AML patients. The introduction of i.v.
busulfan decreases the intra- and inter-individual
variability in systemic busulfan exposure, improving the
safety of BuCy regimen. However, early RRT was still
substantial, especially HVOD. Busulfan and cyclophospha-
mide are mainly metabolized in liver. Both toxic cyclophos-
phamide metabolites and busulfan can decrease the levels
of glutathione (GSH) [4,22]. Combination of these two
alkylating agents may result in an exacerbated risk for
serious hepatic injuries [4]. Recently, to limit RRT and
TRM, non-myeloablative and reduced-intensity condi-
tioning regimens are increasingly used, however, relapse
Table 2 Organ toxicity according to Bearman’s criteria
Grade I or II Grade III or IV
BuCy BuFlu BuCy BuFlu P value
Heart (single/multiple) 4/8 2/4 2/0 0/0 0.048
Bladder 5/8 2/4 0/1 0/0 0.010
Kidneys 0/2 0/1 0/0 0/0 0.500
Lungs 0/0 0/0 0/0 0/0
Liver 4/10 4/5 0/1 0/0 0.165
CNS 0/0 0/1 0/3 0/0 0.618
Mucosa 16/20 15/9 0/0 0/0 0.020
Gut 1/24 10/6 0/2 0/0 0.018
Abbreviations: BuCy, busulfan-cyclophosphamide; BuFlu, busulfan-fludarabine;
CNS, central nervous system.
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becomes more prevalent. Therefore, the challenge is to
develop myeloablative regimens associated with low
TRM and sufficient anti-leukemic effect.
Fludarabine is widely used in chemotherapy of acute
leukemia (especially refractory leukemia) and in condition-
ing regimens for allo-HSCT. Fludarabine has a synergistic
interaction with busulfan through inhibition of DNA ligase
and DNA primase, and prevention of DNA polymerization,
impairing alkylator-induced damage repair. In addition,
fludarabine does not depend on hepatic GSH-stores for its
detoxification. Thus, there are non-overlapping organ
toxicities between fludarabine and busulfan. A growing
body of evidence suggests that fludarabine plus busulfan as
myeloablative or non-myeloablative conditioning regimen
results in a favorable balance between anti-malignancy
efficacy and reduced toxicities [5-12]. In this study, we
observed that the incidence of RRT and regimen-related
death were significantly higher in BuCy regimen compared
with BuFlu regimen in patients with AML-CR1 undergoing
allo-HSCT. BuCy regimen showed higher incidence of
bladder, mucosa and gut adverse events compared with
BuFlu regimen. These results were consistent with previous
studies [8-10]. Surprisingly, we observed that 2 patients
died from heart toxicities and autopsy of one case showed
limited myocardial fibrosis, suggesting that BuCy might be
more toxic to the heart than BuFlu, especially to those with
a history of heart disease. Although total hepatic toxicities
were similar between the two regimens, one patient died of
HVOD in BuCy regimen in our study. No differences in
TRM between the two regimens might be attributed to the
young age and lack of comorbidities of patients in our
cohort. We also observed that the median duration of
neutrophil count below 0.1 × 109/L and platelet count
below 20 × 109/L in BuCy regimen were significantly longer
Figure 1 Cumulative incidence of relapse (A), transplant related mortality (TRM) (B), overall survival (OS) (C) and disease free survival
(DFS) (D). The 5-year cumulative incidence of relapse were 16.5 ± 5.8% and 16.2 ± 5.3% in BuCy and BuFlu group (P = 0.943). The 5-year
cumulative incidence of TRM were 18.8 ± 6.9% and 9.9 ± 6.3% in BuCy and BuFlu group (P = 0.104). The 5-year cumulative OS were 72.3 ± 7.5%
and 81.9 ± 7.0%, respectively, in BuCy and BuFlu group (P = 0.177), and DFS were 67.4 ± 7.6% and 75.3 ± 7.2%, respectively, in BuCy and BuFlu
group (P =0.315).
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than that in BuFlu regimen. Meanwhile, BuCy regimen
required more red blood cells and platelet concentrates
transfusions compared with BuFlu regimen. From these
data, it can be suggested that BuFlu regimen might possess
less RRT and bone marrow toxicities as well as safer than
BuCy regimen. In addition, Russell et al. reported that
single daily intravenous busulfan would be more conveni-
ent and could be achieved with acceptable toxicity com-
pared with traditional 4-times-daily dosing. In this report,
busulfan was administered every 12 hours and associated
with higher peak blood concentration after the first day
and similar toxicity compared with 4-times-daily dosing
(data not shown). Whether this 2-times-daily dosing is
associated with increased anti-leukemic activity remains
to be discussed.
Other than relapse of malignancy, GVHD and infections
remain as the two main causes of death after allo-HSCT. A
shorter duration of neutropenia and faster hematopoietic
recovery may reduce risk of infection after transplants
[23,24]. In the present study, the bone marrow suppression
toxicities were lower in BuFlu regimen than BuCy
regimen. However, the incidence of early infectious post-
transplantation (including bacterial and fungal infections)
did not differ between the two regimens, probably as a
consequence of almost all patients being treated in a sterile
ward for 100 days after transplantation and the short
duration of neutropenia. Some studies suggested that
the conditioning regimens containing fludarabine were
associated with higher incidence of opportunistic infections
such as CMV and EBV after transplantation because of the
immunosuppressive effect of fludarabine [10,25,26]. Here,
we observed that the incidence of CMV and EBV viremia
was similar between BuFlu and BuCy regimens within 6
months after transplantation. During the follow-up period,
there were also no differences in the incidence of CMV and
EBV-associated diseases between the two regimens.
GVHD is a complex pathological process mediated by
allo-reactive donor T cells recognizing the disparate
HLA antigens and involving tissue-specific immune cells
and inflammatory cytokines [27]. The incidence and
severity of GVHD can be influenced by many factors
including age of recipient and donor, HLA typing, source
of donor and stem cells, and conditioning regimens. The
conditioning can provoke the release of inflammatory
factors, which play critical roles in aGVHD [28]. Chae et al.
reported that the incidence and severity of acute and
chronic GVHD were lower in BuFlu regimen compared
with BuCy regimen [9]. However, in a randomized trial, Lee
et al. suggested that the incidence and severity of acute and
chronic GVHD were similar between the two regimens
[14]. In this report, the incidence of I-II° and III-IV°
aGVHD as well as total and extensive cGVHD were also
similar between BuFlu and BuCy regimens.
Some single arm and retrospective comparison studies
suggested that myeloablative BuFlu regimen did not
increase the risk of disease relapse [9,10]. However,
Table 3 Risk factors for OS, DFS, TRM and relapse incidence









Sex male/female NS NS NS NS NS NS NS NS
Genetic subgroups favorable/
intermediate/poor risk/unknown
NS NS NS NS NS NS P = 0.002 P = 0.018
(2.218)
Age ≤30.5/>30.5 years NS NS NS NS NS NS NS NS
Induction Chemotherapy
cycles ≤1/>1 cycles
NS NS NS NS NS NS NS NS
Consolidation chemotherapy
cycles ≤2/>2 cycles
NS NS NS NS NS NS NS NS
Source of stem cells PB /BM + PB NS NS NS NS NS NS NS NS
Source of donors related/unrelated NS NS NS NS NS NS NS NS
Age of donors ≤30.0/>30.0 years NS NS NS NS P = 0.026 NS NS NS
HLA typing matched/mismached NS NS NS NS NS NS P = 0.011 NS
Conditioning regimen BuCy/BuFlu NS NS NS NS NS NS NS NS
MNC(108/Kg) ≤7.33/>7.33 NS NS NS NS NS NS NS NS
CD34 + (106/Kg) ≤6.22/>6.22 NS NS NS NS NS NS NS NS
Acute GVHD With/without P = 0.014 P = 0.018
(5.214)
NS NS P = 0.001 P = 0.006
(18.538)
NS NS
Chronic GVHD With/without NS NS NS NS NS NS NS NS
Abbreviations: OS, overall survival; DFS, disease free survival; TRM, transplant related mortality; BuCy, busulfan-cyclophosphamide; BuFlu, busulfan-fludarabine;BM,
bone marrow; PB, peripheral blood; MNC, mononucleated cell.
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Shimoni et al. reported a non-statistically significant trend
for higher incidence of relapse after BuFlu myeloablative
regimen [13]. Lee et al. reported that BuFlu regimen had
lower relapse-free survival than BuCy regimen [14].
However, these two studies enrolled patients with different
diseases and disease status before transplantation. In this
study, we found no significant difference in relapse rate
between BuCy and BuFlu regimens for AML-CR1 patients.
Based on these results, we concluded that BuFlu and BuCy
had equivalent anti-leukemic activity to AML-CR1 patients
undergoing allo-HSCT.
The survival of patients with AML after allo-HSCT is
influenced by many factors, such as the response to
induction therapy, white blood cell count at diagnosis,
cytogenetics, the status of disease during transplantation,
and conditioning regimens [29,30]. Several single arm and
retrospective comparisons showed that myeloablative regi-
men based on busulfan and fludarabine might be associated
with fewer RRT, lower TRM, and higher survival rates com-
pared with BuCy [8-10]. However, a recent randomized
prospective trial from Lee et al. reported that BuCy regimen
had better 2-year OS and DFS than BuFlu in patients with
leukemia and MDS [14]. In the present randomized
prospective trial, the 5-year cumulative OS and DFS were
81.9 ± 7.0% and 75.3 ± 7.2% in AML-CR1 patients receiving
BuFlu, and were not different from patients receiving BuCy
(72.3 ± 7.5% and 67.4 ± 7.6%). We used similar conditioning
regimen as Lee et al’s study except the schedule of busulfan.
The different results might be attributed to the different
disease composition and disease status in these two studies.
Conclusions
Our randomized prospective trial suggests that BuFlu
regimen is a myeloablative conditioning regimen with
reduced toxicity. It is well tolerated and possesses similar
anti-leukemic activity compared with BuCy in AML-CR1
patients undergoing allo-HSCT.
Abbreviations
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